Ritter Pharmaceuticals (RTTR) Sees Strong Trading Volume

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) shares saw an uptick in trading volume on Thursday . 3,401,886 shares were traded during mid-day trading, an increase of 505% from the previous session’s volume of 561,906 shares.The stock last traded at $1.20 and had previously closed at $0.85.

A number of equities research analysts recently commented on the company. Zacks Investment Research cut Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th. ValuEngine raised Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Maxim Group reaffirmed a “hold” rating on shares of Ritter Pharmaceuticals in a research note on Thursday, December 20th.

The company has a market capitalization of $5.04 million, a P/E ratio of -0.24 and a beta of 1.43.

An institutional investor recently raised its position in Ritter Pharmaceuticals stock. Vanguard Group Inc increased its stake in shares of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) by 300.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,210 shares of the biotechnology company’s stock after purchasing an additional 42,180 shares during the period. Vanguard Group Inc owned approximately 0.98% of Ritter Pharmaceuticals worth $105,000 as of its most recent SEC filing. Institutional investors and hedge funds own 13.69% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Ritter Pharmaceuticals (RTTR) Sees Strong Trading Volume” was first published by WKRB News and is owned by of WKRB News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.wkrb13.com/2019/03/14/ritter-pharmaceuticals-rttr-sees-strong-trading-volume.html.

Ritter Pharmaceuticals Company Profile (NASDAQ:RTTR)

Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.

Featured Article: Dividend

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.